Study Management
SS - 203.02

STANDARD OPERATING PROCEDURE
Pre-study Site Visit (PSV)

Approval: Lynn M. Durham, Ed.D.
President and CEO

04 Feb 2021
(Signature and Date)

Approval: Frederick M. Schnell, MD, FACP
Chief Medical Officer

04 Feb 2021
(Signature and Date)

Issue Date: 01 June 2017
Effective Date: 01 September 2020
Expiration Date: 01 September 2022
Document Review Date: 30 June 2020
Reviewer: Jane Clark, PhD, RN, AOCN, OCN (2020)
Previous Reviewers: Joni Shortt, BSN, RN, CCRC (2017)
Alice Kerber, MN, APRN (2014)
Primary Author: Anita Clavier, BSN, MPH (2013)

1. INTRODUCTION AND PURPOSE

Georgia CORE is responsible for ensuring that Research Network site Investigators and staff for studies are evaluated for capabilities, patient population, resources, and commitment to participation in conducting the study at the site.

The purpose of the Pre-study Site Visit (PSV) is to:

- Meet with the Research Network site investigator and staff to review their qualifications for the study.
- Discuss the availability of patients for enrollment and the presence of any similar/competing studies,
- Assess the facilities and capabilities of the Research Network site for implementing the study.
• Evaluate the commitment of the Research Network site to participate in the study.

2. SCOPE

This SOP applies to the procedures for conducting the pre-study site visit for clinical studies subject to investigational new drug (IND) regulations for drugs and biologics and those which are IND exempt during all investigational phases of development. The SOP describes the steps followed by Georgia CORE from the time a PSV is scheduled until all follow-up activities associated with the visit have been completed. An exemption to the PSV is available if the Research Network site has participated in a study with Georgia CORE within the previous 12 months and no major changes at the site have occurred based on a telephone assessment.

3. APPLICABLE REGULATIONS AND GUIDELINES

The Code of Federal Regulations and the International Conference on Harmonization, Good Clinical Practice: Consolidated Guideline and selected program and guidance documents apply to this SOP (Appendix A).

4. REFERENCES TO OTHER APPLICABLE SOPS

SM - 201  Assessing Protocol Feasibility
SS - 202  Investigator Selection
SS - 204  Site Initiation Visit
SM- 301  Communication
SM -303  Documentation and Records Retention

5. ATTACHMENTS

A.  Agenda for Pre-study Site Visit (PSV)
B.  Checklist of Activities associated with the Pre-study Site Visit (PSV)
C.  Pre-study Site Visit Follow-up

6. RESPONSIBILITY

This SOP applies to those members of Georgia CORE administration and staff members and consultants involved in identifying, qualifying, and recommending potential investigators for clinical studies. Included may be one or more of the following:
• President and CEO
• Chief Medical Officer
• Georgia CORE staff and consultants
• Research Network site Investigator
7. **DEFINITIONS**
   The following definitions apply to this SOP (Appendix B):
   - Clinical trial/study
   - Institutional Review Board (IRB)
   - Investigator
   - Investigator’s Brochure
   - Protocol
   - Sponsor
   - Subinvestigator

8. **PROCESS OVERVIEW**
   A. Preparing for the pre-study site visit
   B. Conducting the pre-study site visit
   C. Following-up after the pre-study site visit

9. **PROCEDURES**
   A. **Identifying Potential Investigators**
      - Georgia CORE staff and consultants
      - Ensure that the Research Network site Master Clinical Research Agreement including the confidentiality agreement with Georgia CORE is current.
      - If a Master Clinical Research Agreement is not in effect, a study-specific agreement incorporating the confidentiality agreement may be substituted.
      - If the Master Clinical Research Agreement is not in effect at the time of the PSV request, the Research Network site Investigator or authorized agent for the site must execute the appropriate document.
      - Ensure that the Research Network site has received the protocol, budget, informed consent, case report forms, and other study documents, if available.
      - Schedule the PSV with the Research Network site and discuss any areas of special interest that require advance scheduling, such as:
        - availability of Investigator and required staff,
        - visiting the treatment site (clinic or hospital), pharmacy, laboratory, and medical records department,
        - seeing any specialized equipment needed to implement the study,
        - meeting briefly with ancillary personnel involved in the specialized data collection, and
        - visiting any ancillary facilities.
Complete the pre-study visit agenda and review the agenda with the Research Network site personnel prior to the visit (Attachment A: Agenda Template for the Pre-study Site Visit).

If not on file, obtain copies of current curriculum vitae and resumes for Research Network site Investigators, Subinvestigators, and key study staff.

B. Conducting the Pre-study Site Visit

Georgia CORE staff and consultants  Meet with the Research Network site Investigators, and key research staff identified by the Investigator to review the protocol synopsis and any other available study documents.

Tour the research facilities where the clinical trial will be conducted with the Research Network site Investigator and/or key site representatives.

Complete the Checklist of Activities Associated with the Pre-study Site Visit (Attachment A).

C. Following up After the Pre-study Site Visit

Georgia CORE staff and consultants  Complete the pre-study site visit follow-up summary, to document the pre-study site visit. Provide copies to the Georgia CORE Chief Medical Officer and to the Investigator initiating the study (Attachment C: Pre-Study Site Visit Follow-up).

10. History of Changes

<table>
<thead>
<tr>
<th>Version Number</th>
<th>Section Number</th>
<th>Modification</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>203.01</td>
<td>All</td>
<td>Original Version</td>
<td></td>
</tr>
<tr>
<td>203.01</td>
<td>AB</td>
<td>No change necessary</td>
<td>09 March 2012</td>
</tr>
<tr>
<td>203.01</td>
<td>3, Attachment B</td>
<td>No change necessary</td>
<td>01 July 2014</td>
</tr>
<tr>
<td>203.01</td>
<td>All</td>
<td>No change necessary</td>
<td>21 March 2017</td>
</tr>
<tr>
<td>203.02</td>
<td>All</td>
<td>Edited for clarity and logical consistency</td>
<td>30 June 2020</td>
</tr>
</tbody>
</table>
### ATTACHMENT A:
Agenda for Pre-study Site Visit

<table>
<thead>
<tr>
<th>Time Frame</th>
<th>Agenda Item</th>
<th>Responsible Parties</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 minutes</td>
<td>Welcome and Introductions</td>
<td>Georgia CORE Site Investigator and key personnel Sponsor personnel, if applicable</td>
</tr>
<tr>
<td>30 minutes</td>
<td>Tour of Facilities</td>
<td>Georgia CORE Site key personnel Sponsor personnel, if applicable</td>
</tr>
<tr>
<td>30 minutes</td>
<td>Review of Protocol or Protocol Synopsis</td>
<td>All</td>
</tr>
<tr>
<td></td>
<td>Informed Consent and Case Report Forms</td>
<td>Georgia CORE Site Investigator and key personnel Sponsor personnel, if applicable</td>
</tr>
<tr>
<td></td>
<td>Discussion of Roles and Responsibilities of Georgia CORE, Research Network site and Sponsor, if applicable</td>
<td></td>
</tr>
<tr>
<td>60 minutes</td>
<td>Site Qualifications including Availability of SOPs</td>
<td>Georgia CORE Site Investigator and key personnel Sponsor personnel, if applicable</td>
</tr>
<tr>
<td>15 minutes</td>
<td>Time Line for the Study Strategies for Patient Recruitment</td>
<td>All</td>
</tr>
<tr>
<td>5 minutes</td>
<td>Review of Action Items and Next Steps</td>
<td>Georgia CORE Site Investigator and key personnel Sponsor personnel, if applicable</td>
</tr>
<tr>
<td>5 minutes</td>
<td>Summary</td>
<td>Georgia CORE</td>
</tr>
</tbody>
</table>
Site Investigator
ATTACHMENT B: Checklist of Activities Associate with the Pre-study Site Visit

1. Before the pre-study site visit

   Request several potential meeting dates and times to accommodate as many key personnel as possible.

   Ensure that key site personnel receive copies of the protocol synopsis and other protocol documents including Informed Consent and Case Report Form, if available, for review and comment.

   Prepare information on:
   - Georgia CORE, Principal Investigator, Research Network participants
   - An overview of the protocol
   - Contractual obligations
   - Roles and responsibilities of parties in particular, IRB and regulatory responsibilities, registration of the study
   - Relevant Georgia CORE or Sponsor SOPs, if applicable
   - Names of key contacts, telephone numbers, and e-mail addresses for Georgia CORE staff and sponsor, if applicable

2. During the pre-study site visit

   Tour the facilities including:
   - Exam rooms for subject evaluation and treatment
   - Laboratory area
   - Any special testing areas
   - Pharmacy; satellite pharmacy, if appropriate
   - Hospital unit, if applicable
   - Work areas for research staff
   - Storage areas for study drug
   - Storage areas for supplies
   - Storage areas for study documents
   - Storage areas for specimens, if applicable
   - Data entry area, if appropriate

   Be prepared to discuss the following:
   - Comments and questions from site personnel's review of the protocol
   - Any requests for site-specific modifications to the protocol
   - IRB (central or local)
   - Laboratory (central or local)
   - Provision for any specialized procedures
   - Any specialized data entry procedures
   - Storage space required for study drug, specialized equipment, computers, etc.
   - Specimens processing and storage
   - IATA certifications for applicable staff

   Provide an overview of the management process for the study, including:
• Georgia CORE and sponsor, if applicable, responsibilities (contractual and SOPs)
• Monitoring plan
• Communication
• Overview of data management

Discuss the following:
• The benefits of the study for the site's patient population
• Expected enrollment, strategies for patient recruitment
• Publication policy
• Availability of qualified, experienced and sufficient site personnel to conduct this study
• After study initiation, the site training plan for ancillary research and facility personnel involved in the study
• List of generic clinical trials with number of patients required, recruited and completed (overall and completed recently)
• Results of any FDA or other site audits, any warnings or other findings if audit completed
• Exclusion from any federal health program, such as Medicare or Medicaid
• Site capability for electronic data capture
• Any policies regarding access to electronic medical records which may impact monitor’s access to medical records
• Copies of any publications by research staff relevant to the clinical study under consideration
• Estimate number of potential study participants, any concerns regarding study participant recruitment
• Anticipated time line for the study
• Information on key dates, such as:
  - Investigator’s meeting
  - Study initiation visit
  - Study drug availability, if applicable
  - Targeted end date for patient enrollment
  - Georgia CORE chain of command and communication plan

Determine if there is any other information that the site requires

Discuss the IRB review process, and get copies of the IRB SOPs and Federal Wide Assurance (FWA) number, if applicable

3. Pre-study site visit

Compile the pre-study site visit follow up summary; review with the Chief Medical Officer if necessary to determine appropriateness of site participation

Notify the site in writing if selected to participate in the clinical trial.

Once the protocol is finalized, prepare the following and provide to site:
• Informed consent form
• IRB submission/approval
• Final budget

Submit the clinical trial agreement/addendum to the site for signoff. Distribute executed copies to all parties.
**ATTACHMENT C:**
**Pre-study Site Visit Form**

<table>
<thead>
<tr>
<th>Investigator:</th>
<th>Indication:</th>
<th>Protocol no:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial site:</td>
<td>CRA:</td>
<td>Site no:</td>
</tr>
<tr>
<td>Inv Product:</td>
<td>Date of last visit:</td>
<td>Visit Date:</td>
</tr>
</tbody>
</table>

Site personnel present:

Georgia CORE or Georgia CORE designated personnel present:

List other site personnel that will be working on this study, including position and contact information.

<table>
<thead>
<tr>
<th>Action items resulting from present visit</th>
<th>Responsible Personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. CRA judgement regarding motivation and attitude of the site.
   Please provide details including why this site should or should not be included in this trial and any major issues that need to be overcome.

Comments:
Protocol and Patient Population

2. Were the nature, design and time frame of the proposed clinical study discussed with the Investigator? Please provide details regarding the contents of the discussion, any major questions or issues, etc.

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

3. Does the Investigator and staff have experience with FDA regulated human subject research (number and type of studies)? Please provide list of clinical trials with number of patients required, recruited and completed (overall and completed recently).

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

4. Does the site have the patient population to meet the target enrollment for the study? Please provide details regarding the method of recruitment, existing database of patients, referral network, activity logs, chart reviews, etc.

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:
### Study Personnel

5. Are the site’s personnel sufficiently qualified to conduct the study? Please provide details regarding experience, training, certifications, work on prior studies, standard operating procedures, etc.

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

6. Does the site have sufficient personnel resources to conduct the study? Please provide details regarding availability, time to conduct study, available for monitoring visits, conflicting studies, etc.

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

7. Was the GCP/source document verification discussed with the Investigator? Please provide details regarding nature of discussion, including GCP, source verification, financial disclosure, reporting of SAEs,

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

8. Has the Investigator or staff had regulatory issues or problems in prior studies or been exempted from federal health care programs, such as Medicare or Medicaid? Please provide details regarding FDA or Sponsor audits, any 483s, any sanctions from a Regulatory Agency, etc.

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:
### Investigational Product

9. Are the drug storage facilities adequate?  
   Please provide assessment of the drug storage facilities, e.g. accessibility, condition, location, personnel, drug accountability procedures, etc.  
<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

### Laboratory

10. Are the laboratory processes and procedures adequate?  
    Please provide details regarding labs reviewed, location, sample collection procedures, accreditation, storage, normal values, special equipment, etc.  
    | Yes | No | Not done | Not applicable |
    |-----|----|---------|----------------|

Comments:

### Location and Source Documentation

11. Does the site have adequate space facilities to conduct the study?  
    Please provide details regarding appropriate space for monitoring, record-keeping, conducting patient visits, special equipment, logistics of protocol procedures between various co/investigators (e.g. radiologist, surgeon) etc.  
    | Yes | No | Not done | Not applicable |
    |-----|----|---------|----------------|

Comments:

12. Are source documents readily available?  
    Please provide details regarding accessibility of records, location of records, use of hospital or shadow charts, etc.  
    | Yes | No | Not done | Not applicable |
    |-----|----|---------|----------------|

Comments:
### IRB Approval and Clinical Study Agreements

<table>
<thead>
<tr>
<th>13. Are the IRB and contract/budget processes compatible with study timelines?</th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please provide details regarding processes, timeframe for approval, special requirements, whether site has worked with Georgia CORE previously, etc. Also specify the type of IRB being used, timetable of meetings and deadlines for submission. Note if there are local IRB requirements and estimated timetable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments:

### Electronic CRF

(Check Not Applicable if not using e-CRF)

<table>
<thead>
<tr>
<th>14. Does the site have the necessary computer equipment and knowledge to conduct the study (for e-CRF trials)?</th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please provide details regarding availability or need for computer equipment, high speed access, computer training, prior experience with e-CRF, etc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments:

<table>
<thead>
<tr>
<th>15. Was the e-CRF assessment completed?</th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please provide details regarding formal e-CRF assessments conducted by IT support department.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments:

<table>
<thead>
<tr>
<th>16. Is the site’s electronic records and computer network system Title 21, Part 11 compliant?</th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
</table>

Comments:

### Miscellaneous

<table>
<thead>
<tr>
<th>17. Tissue Banking</th>
<th>Yes</th>
<th>No</th>
<th>Not done</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the site have the capability to obtain tissue samples for DNA banking? Detail any logistics requirements, etc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments: